Candidiasis News and Research

RSS
Candiadiasis, or Thrush, is a fungal infection caused by a group of yeast. There is a score of Candida species, the commonest of which is Candida albicans. They normally inhabit the surfaces and mucus linings of the human body. This includes mouth, vaginal cavity gastrointestinal tract etc.
FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

Research shows how mucosal surfaces in body respond to C. albicans to prevent damage

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

EADV spring symposium: Bioalliance Pharma presents Sitavig study results

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

FDA's PADAC supports approval of BREO ELLIPTA as once-daily inhaled treatment for COPD

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

Invokana tablets receive FDA approval to treat adults with type 2 diabetes

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Risk factors for invasive candidiasis in infants clarified

Risk factors for invasive candidiasis in infants clarified

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

Oral Candida infection weakens tooth enamel

Oral Candida infection weakens tooth enamel

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

NovaDigm announces data from NDV-3 vaccine Phase 1 study on Candida and Staph infections

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

BioAlliance, Vestiq enter licensing agreement to commercialize Oravig in the US

Friendly bacteria: do we really need to eat probiotic yogurts?

Friendly bacteria: do we really need to eat probiotic yogurts?

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

BioAlliance Pharma, Vestiq enter license agreement for Oravig to treat oropharyngeal candidiasis

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis